Using Biotechnology with AI for Drug Discovery helps create a novel protein that would usually have taken 500 million years to naturally happen. One day will we ‘program’ biology as easily as we write computer code?
Key Points and Main Takeaways
Amazon Web Services (AWS) has announced the launch of a new AI model, ESM-3, by a company called EvolutionaryScale. This milestone aims to push the boundaries of biology and biotechnology using machine learning. One highlight is that ESM-3 has trained on more than 650 million protein sequences, which is a substantial leap forward in this field. According to Amazon, ESM-3 not only enhances the accuracy of protein structure predictions but can also detect functional insights that were previously hard to attain.
This development taps into AWS’s computational power, making it scalable and accessible for various research applications. The original article by AWS emphasizes that ESM-3 can expedite drug discovery and personalized medicine, among other applications.
Pros
- Scalability: Leveraging AWS’s computation, ESM-3 is scalable, making high-level biological research more accessible.
- Accuracy: With training on over 650 million protein sequences, ESM-3 increases the precision of protein structure predictions.
- Functional Insights: The model can uncover detailed functional insights into protein structures, aiding in complex biological research.
- Applications in Medicine: Potential applications include speeding up drug discovery and enabling personalized treatment plans.
Cons
- Complexity: The model’s complexity might require specialized knowledge and skill to fully utilize.
- Resource-Intensive: High-level computations might still be resource-intensive, even with AWS’s scalability.
Question to Consider
As advancements like ESM-3 bring new potential to biological research and medicine, what are the ethical and practical considerations we must address to ensure these powerful tools are used responsibly and equitably?
Image Credit: Unsplash
